Remote Ischemic Conditioning Paired With Endovascular Treatment for Acute Ischemic Stroke (REVISE-2)
Primary Purpose
Acute Stroke
Status
Unknown status
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Remote ischemic conditioning.
Endovascular treatment.
Sham remote ischemic conditioning
Sponsored by
About this trial
This is an interventional treatment trial for Acute Stroke focused on measuring Acute ischemic stroke, Endovascular treatment, Remote ischemic conditioning
Eligibility Criteria
Inclusion Criteria:
- Acute ischemic stroke where patient is ineligible for intravenous thrombolytic treatment or the treatment is contraindicated, or where patient has received intravenous thrombolytic therapy without recanalization;
- Suspected proximal anterior circulation occlusion;
- No remarkable pre-stroke functional disability (mRS ≤ 1);
- Baseline NIHSS score obtained prior to randomization must be ≥6;
- Age ≥18 and ≤ 80;
- Patient treatable within 24 hours of symptom onset;
- Informed consent obtained from patient or acceptable patient's surrogate
Exclusion Criteria:
- Identified hemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant therapy with INR > 3.0;
- Baseline platelet count < 30*109/L;
- Baseline blood glucose of < 2.7mmol/L or >22.2mmol/L;
- Renal insufficiency with creatinine ≥ 265 umol/L;
- Severe, sustained hypertension (SBP > 185 mmHg or DBP > 110 mmHg);
- Rapidly improving symptoms at the discretion of the investigator;
- Seizures at stroke onset which would preclude obtaining a baseline NIHSS;
- Serious, advanced, or terminal illness with anticipated life expectancy of less than one year;
- History of life threatening allergy to contrast medium, Nickel, Titanium metals or their alloys;
- Woman of childbearing potential who is known to be pregnant or lactating or who has a positive pregnancy test on admission;
- Subject participating in a study involving other drug or device trial study;
- Patients with a pre-existing neurological or psychiatric disease that would confound the neurological or functional evaluations;
- Unlikely to be available for 90-day follow-up;
- Contraindication for remote ischemic conditioning: severe soft tissue injury, fracture, or peripheral vascular disease in the upper limbs;
- Hypodensity on CT or restricted diffusion amounting to an ASPECTS score of <7 on noncontrast CT or <6 on DWI MRI;
- CT or MRI evidence of hemorrhage;
- Significant mass effect with midline shift on CT or MRI scans;
- Angiogram shows arterial tortuosity, pre-existing stent, and/or other arterial disease, which would prevent the device from reaching the target vessel and/or preclude safe recovery of the device;
- Subjects with artery occlusions in multiple vascular territories;
- Evidence of intracranial tumor.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Sham Comparator
Arm Label
RIC group
Sham group
Arm Description
RIC (remote ischemic conditioning) paired with endovascular treatment.
Sham RIC (remote ischemic conditioning) paired with endovascular treatment.
Outcomes
Primary Outcome Measures
Cerebral infarction volume.
The cerebral infarction volume is evaluated on cerebral imaging.
Secondary Outcome Measures
The proportion of enrolled subjects that completed all the designed RIC procedures.
Nine times of RIC or sham RIC interventions are planned to be applied to each subject pre and post-endovascular treatment.
The severity of global disability at 90 days, as assessed by modified Rankin scale (mRS).
The mRS is an ordinal, graded interval scale that assigns patients among 7 global disability levels, which ranging from 0 (no symptom) to 5 (severe disability) and 6 (death).
Change in NIHSS.
NIHSS will be assessed by certified study investigator who are blind to the treatment assignment at baseline (pre-operation), 24±6 hrs, 5 to 7 days or discharge if earlier, and 90±7 days post-recanalization.
Symptomatic Intracerebral Hemorrhage.
Deterioration in NIHSS score of ≥4 points within 24 hours from treatment and evidence of intraparenchymal hemorrhage type 2 in imaging scans.
Safety - Assessment of adverse events and serious adverse events.
Assessment of adverse events and serious adverse events.
Full Information
NCT ID
NCT03045055
First Posted
February 3, 2017
Last Updated
July 23, 2020
Sponsor
Capital Medical University
Collaborators
Shengli Oilfield Central Hospital
1. Study Identification
Unique Protocol Identification Number
NCT03045055
Brief Title
Remote Ischemic Conditioning Paired With Endovascular Treatment for Acute Ischemic Stroke
Acronym
REVISE-2
Official Title
A Proof-of-Concept Study Assessing the Safety and Efficacy of Remote Ischemic Conditioning for Acute Ischemic Stroke Patients Undergoing Endovascular Treatment
Study Type
Interventional
2. Study Status
Record Verification Date
July 2020
Overall Recruitment Status
Unknown status
Study Start Date
August 1, 2020 (Anticipated)
Primary Completion Date
December 31, 2022 (Anticipated)
Study Completion Date
March 31, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Capital Medical University
Collaborators
Shengli Oilfield Central Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Ischemic stroke, which is due to the occlusion of a cerebral blood vessel, comprises nearly 80-90% of all strokes. Currently, reperfusion of the salvageable tissue via thrombolytic drug or endovascular treatment is the most effective strategy to reduce brain damage. However, after recanalizing the occluded vessels, subsequent reperfusion injury is inevitable. It may not only weaken the therapeutic effects of timely reperfusion but also impede patients' recovery. Moreover, thousands of neuroprotective drugs effective in experimental models have been proved to be unsuccessful in clinical trials. Therefore, effective strategies are urgently needed to prevent and treat cerebral reperfusion injury and further improve the prognosis of acute ischemic stroke.
Researchers applied remote ischemic conditioning to mouse model of focal cerebral reperfusion injury and found that it could reduce cerebral infarct size. And clinical researches demonstrated that remote ischemic conditioning was an effective strategy to improve cerebral perfusion and prevent recurrent stroke in patients with ischemic stroke. However, whether remote ischemic conditioning is safe and effective in protecting patients with large-vessel ischemic stroke and undergoing endovascular treatment is still unclear. The investigators' hypothesis is that RIC is a safe and effective strategy to reduce brain injuries in stroke patients undergoing endovascular treatment.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Stroke
Keywords
Acute ischemic stroke, Endovascular treatment, Remote ischemic conditioning
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
180 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
RIC group
Arm Type
Experimental
Arm Description
RIC (remote ischemic conditioning) paired with endovascular treatment.
Arm Title
Sham group
Arm Type
Sham Comparator
Arm Description
Sham RIC (remote ischemic conditioning) paired with endovascular treatment.
Intervention Type
Device
Intervention Name(s)
Remote ischemic conditioning.
Other Intervention Name(s)
RIC
Intervention Description
The RIC procedure consists of four cycles of unilateral arm ischemia for 5 minutes, which was followed by reperfusion for another 5 minutes. The procedure is performed with an electric, autocontrol device with a cuff that inflated to a pressure of 200 mmHg during the ischemia period. RIC is performed before recanalization of the occluded artery, immediately following successful recanalization, and once daily for the subsequent 7 days.
Intervention Type
Procedure
Intervention Name(s)
Endovascular treatment.
Intervention Description
Endovascular treatment of acute ischemic stroke is performed by experienced neuroradiologist according to the latest guideline from American Heart Association and American Stroke Association.It includes thrombectomy, intra-arterial thrombolysis, thrombus aspiration, stenting and balloon angioplasty.
Intervention Type
Device
Intervention Name(s)
Sham remote ischemic conditioning
Other Intervention Name(s)
Sham RIC
Intervention Description
The sham RIC procedure consists of four cycles of unilateral arm ischemia for 5 minutes, which was followed by reperfusion for another 5 minutes. The procedure is performed with an electric, autocontrol device with a cuff that inflated to a pressure of 30 mmHg during the ischemia period. Sham RIC is performed before recanalization of the occluded artery, immediately following successful recanalization, and once daily for the subsequent 7 days.
Primary Outcome Measure Information:
Title
Cerebral infarction volume.
Description
The cerebral infarction volume is evaluated on cerebral imaging.
Time Frame
7 days after stroke onset.
Secondary Outcome Measure Information:
Title
The proportion of enrolled subjects that completed all the designed RIC procedures.
Description
Nine times of RIC or sham RIC interventions are planned to be applied to each subject pre and post-endovascular treatment.
Time Frame
0-7 days.
Title
The severity of global disability at 90 days, as assessed by modified Rankin scale (mRS).
Description
The mRS is an ordinal, graded interval scale that assigns patients among 7 global disability levels, which ranging from 0 (no symptom) to 5 (severe disability) and 6 (death).
Time Frame
0-90 days.
Title
Change in NIHSS.
Description
NIHSS will be assessed by certified study investigator who are blind to the treatment assignment at baseline (pre-operation), 24±6 hrs, 5 to 7 days or discharge if earlier, and 90±7 days post-recanalization.
Time Frame
0-90 days.
Title
Symptomatic Intracerebral Hemorrhage.
Description
Deterioration in NIHSS score of ≥4 points within 24 hours from treatment and evidence of intraparenchymal hemorrhage type 2 in imaging scans.
Time Frame
0-90 days.
Title
Safety - Assessment of adverse events and serious adverse events.
Description
Assessment of adverse events and serious adverse events.
Time Frame
0-90 days.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Acute ischemic stroke where patient is ineligible for intravenous thrombolytic treatment or the treatment is contraindicated, or where patient has received intravenous thrombolytic therapy without recanalization;
Suspected proximal anterior circulation occlusion;
No remarkable pre-stroke functional disability (mRS ≤ 1);
Baseline NIHSS score obtained prior to randomization must be ≥6;
Age ≥18 and ≤ 80;
Patient treatable within 24 hours of symptom onset;
Informed consent obtained from patient or acceptable patient's surrogate
Exclusion Criteria:
Identified hemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant therapy with INR > 3.0;
Baseline platelet count < 30*109/L;
Baseline blood glucose of < 2.7mmol/L or >22.2mmol/L;
Renal insufficiency with creatinine ≥ 265 umol/L;
Severe, sustained hypertension (SBP > 185 mmHg or DBP > 110 mmHg);
Rapidly improving symptoms at the discretion of the investigator;
Seizures at stroke onset which would preclude obtaining a baseline NIHSS;
Serious, advanced, or terminal illness with anticipated life expectancy of less than one year;
History of life threatening allergy to contrast medium, Nickel, Titanium metals or their alloys;
Woman of childbearing potential who is known to be pregnant or lactating or who has a positive pregnancy test on admission;
Subject participating in a study involving other drug or device trial study;
Patients with a pre-existing neurological or psychiatric disease that would confound the neurological or functional evaluations;
Unlikely to be available for 90-day follow-up;
Contraindication for remote ischemic conditioning: severe soft tissue injury, fracture, or peripheral vascular disease in the upper limbs;
Hypodensity on CT or restricted diffusion amounting to an ASPECTS score of <7 on noncontrast CT or <6 on DWI MRI;
CT or MRI evidence of hemorrhage;
Significant mass effect with midline shift on CT or MRI scans;
Angiogram shows arterial tortuosity, pre-existing stent, and/or other arterial disease, which would prevent the device from reaching the target vessel and/or preclude safe recovery of the device;
Subjects with artery occlusions in multiple vascular territories;
Evidence of intracranial tumor.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Xunming Ji, MD PhD
Phone
861013120136877
Email
jixunming@vip.163.com; zhaowb.cmu@qq.com
First Name & Middle Initial & Last Name or Official Title & Degree
Wenbo Zhao, MD Candidate
Phone
861015810766407
Email
zhaowb.cool@163.com
12. IPD Sharing Statement
Plan to Share IPD
Yes
Citations:
PubMed Identifier
27766474
Citation
Hausenloy DJ, Barrabes JA, Botker HE, Davidson SM, Di Lisa F, Downey J, Engstrom T, Ferdinandy P, Carbrera-Fuentes HA, Heusch G, Ibanez B, Iliodromitis EK, Inserte J, Jennings R, Kalia N, Kharbanda R, Lecour S, Marber M, Miura T, Ovize M, Perez-Pinzon MA, Piper HM, Przyklenk K, Schmidt MR, Redington A, Ruiz-Meana M, Vilahur G, Vinten-Johansen J, Yellon DM, Garcia-Dorado D. Ischaemic conditioning and targeting reperfusion injury: a 30 year voyage of discovery. Basic Res Cardiol. 2016 Nov;111(6):70. doi: 10.1007/s00395-016-0588-8. Epub 2016 Oct 20.
Results Reference
background
PubMed Identifier
28174194
Citation
Zhao W, Meng R, Ma C, Hou B, Jiao L, Zhu F, Wu W, Shi J, Duan Y, Zhang R, Zhang J, Sun Y, Zhang H, Ling F, Wang Y, Feng W, Ding Y, Ovbiagele B, Ji X. Safety and Efficacy of Remote Ischemic Preconditioning in Patients With Severe Carotid Artery Stenosis Before Carotid Artery Stenting: A Proof-of-Concept, Randomized Controlled Trial. Circulation. 2017 Apr 4;135(14):1325-1335. doi: 10.1161/CIRCULATIONAHA.116.024807. Epub 2017 Feb 7.
Results Reference
background
PubMed Identifier
30009202
Citation
Zhao W, Che R, Li S, Ren C, Li C, Wu C, Lu H, Chen J, Duan J, Meng R, Ji X. Remote ischemic conditioning for acute stroke patients treated with thrombectomy. Ann Clin Transl Neurol. 2018 Jun 6;5(7):850-856. doi: 10.1002/acn3.588. eCollection 2018 Jul.
Results Reference
background
PubMed Identifier
32166195
Citation
Zhao W, Wu C, Dornbos D 3rd, Li S, Song H, Wang Y, Ding Y, Ji X. Multiphase adjuvant neuroprotection: A novel paradigm for improving acute ischemic stroke outcomes. Brain Circ. 2020 Feb 18;6(1):11-18. doi: 10.4103/bc.bc_58_19. eCollection 2020 Jan-Mar.
Results Reference
background
PubMed Identifier
30656197
Citation
Zhao W, Li S, Ren C, Meng R, Jin K, Ji X. Remote ischemic conditioning for stroke: clinical data, challenges, and future directions. Ann Clin Transl Neurol. 2018 Nov 15;6(1):186-196. doi: 10.1002/acn3.691. eCollection 2019 Jan.
Results Reference
background
Learn more about this trial
Remote Ischemic Conditioning Paired With Endovascular Treatment for Acute Ischemic Stroke
We'll reach out to this number within 24 hrs